Management of Pulmonary Tuberculosis
For drug-susceptible pulmonary tuberculosis in adults, use the novel 4-month regimen (2 months of isoniazid, rifampin, pyrazinamide, and moxifloxacin followed by 2 months of isoniazid, rifampin, and moxifloxacin) rather than the traditional 6-month regimen. 1
Drug-Susceptible Pulmonary TB
Adults
The 2025 ATS/CDC/ERS/IDSA guidelines represent a paradigm shift in TB treatment, moving away from the 40-year standard of 6-month therapy 1. The new 4-month regimen incorporates moxifloxacin into the traditional backbone, allowing for treatment shortening while maintaining efficacy for morbidity and mortality outcomes.
Key regimen details:
- Intensive phase (2 months): Isoniazid + Rifampin + Pyrazinamide + Moxifloxacin
- Continuation phase (2 months): Isoniazid + Rifampin + Moxifloxacin
This represents a 33% reduction in treatment duration, significantly improving quality of life through shorter exposure to medications and reduced pill burden 1, 2.
Children and Adolescents (3 months to 16 years)
For children with nonsevere TB without MDR/RR-TB suspicion, use the 4-month regimen of 2HRZ(E)/2HR instead of the traditional 6-month regimen (strong recommendation, moderate certainty) 1.
This shortened regimen:
- Uses standard-dose isoniazid, rifampin, pyrazinamide, with or without ethambutol for 2 months
- Followed by isoniazid and rifampin for 2 months
- Applies to both pulmonary and extrapulmonary disease (except CNS involvement)
Drug-Resistant Pulmonary TB
Rifampin-Resistant, Fluoroquinolone-Susceptible TB
For adolescents ≥14 years and adults with rifampin-resistant, fluoroquinolone-susceptible pulmonary TB, use the 6-month BPaLM regimen (Bedaquiline + Pretomanid + Linezolid + Moxifloxacin) rather than 15-month or longer regimens (strong recommendation, very low certainty) 1.
This represents a dramatic improvement in quality of life, reducing treatment from 15+ months to just 6 months with an all-oral regimen 1, 2. The WHO has endorsed similar shortened regimens (6-9 months) for drug-resistant TB, eliminating the need for injectable agents that were standard for decades 2.
Alternative Drug-Resistant Regimens
For other drug-resistant patterns, the BPaL regimen (without moxifloxacin) and regimens containing clofazimine and delamanid are now available options 2.
Treatment Monitoring Algorithm
Monthly clinical assessments should include:
- Adherence evaluation - Direct inquiry about missed doses, barriers to compliance
- Symptom progression - Cough, fever, weight changes, hemoptysis
- Adverse event screening:
- Hepatotoxicity: Nausea, vomiting, jaundice, abdominal pain
- Peripheral neuropathy: Numbness, tingling (especially with isoniazid)
- Visual changes: Color discrimination, acuity (with ethambutol)
- QT prolongation risk: Palpitations, syncope (with bedaquiline, moxifloxacin)
- Bacteriological monitoring - Sputum cultures at 2 months minimum 3
Critical Pitfalls to Avoid
Do not use the old 6-month regimen when 4-month regimens are appropriate - This unnecessarily prolongs treatment and increases adverse event exposure 1.
Do not use injectable agents for drug-resistant TB when all-oral regimens are available - Injectable agents have worse tolerability and outcomes 2.
Do not delay treatment initiation for drug susceptibility testing in drug-susceptible settings - Begin empiric therapy while awaiting results, but ensure molecular testing (GeneXpert or equivalent) is performed to detect resistance early 3, 4.
Do not forget pyridoxine supplementation - Vitamin B6 prevents isoniazid-induced peripheral neuropathy, especially in high-risk patients (diabetes, HIV, malnutrition, pregnancy) 4.
Adherence Enhancement Strategies
Directly observed therapy (DOT) remains standard, but virtual DOT using digital technologies offers a more patient-centered approach without compromising outcomes 5. Implement comprehensive barrier assessments monthly including:
- Transportation difficulties
- Work/school conflicts
- Medication side effects
- Social support deficits
- Substance use issues
Address identified barriers with targeted interventions rather than generic adherence counseling 3, 6.
End-of-Treatment Assessment
At treatment completion, perform:
- Clinical symptom resolution verification
- Chest imaging to document radiographic improvement
- Final sputum culture to confirm bacteriological cure
- Public health notification for contact tracing completion 3
The shift to shorter, all-oral regimens represents the most significant advance in TB treatment in four decades, directly improving mortality risk through better adherence and quality of life through reduced treatment burden 1, 2.